AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower respiratory tract infection (LRTI) caused by RSV.
{iframe}https://pipelinereview.com/index.php/2019020570460/Antibodies/US-FDA-grants-Breakthrough-Therapy-Designation-for-potential-next-generation-RSV-medicine-MEDI8897.html{/iframe}